IGM Biosciences price target lowered to $1 from $2 at Truist
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2025
0mins
Source: Yahoo Finance
Truist's Price Target Adjustment: Truist has lowered the price target for IGM Biosciences (IGMS) from $2 to $1 while maintaining a Hold rating, reflecting updates based on Q1 financial results and future outlook.
Company Developments: The firm is awaiting any announcements regarding a strategic pivot from IGM Biosciences, amidst reports of increased net loss, termination of a lease agreement, and workforce cuts.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
